Cam­bridge star Ma­gen­ta teams up with Hei­del­berg on bone mar­row R&D pact that in­cludes $334M in po­ten­tial mile­stones

High-fly­ing Cam­bridge up­start Ma­gen­ta Ther­a­peu­tic has inked an ex­clu­sive deal with a Ger­man biotech to work on drugs that might im­prove bone mar­row trans­plants for pa­tients.

Ma­gen­ta is team­ing up with Hei­del­berg Phar­ma, com­bin­ing its stem cell plat­form with Hei­del­berg’s pro­pri­etary AT­AC (An­ti­body Tar­get­ed Aman­itin Con­ju­gates) plat­form. The duo will ap­ply their tech across up to four tar­gets, with the hope of de­vel­op­ing an­ti­body drug con­ju­gates.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN